Combination immunotherapy and targeted therapy for advanced colorectal cancer
Part of Cancer clinical trials.
This trial tests a combination of three new drugs (SHR-1701, SHR2554, and BP102) for people with metastatic colorectal cancer. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to other parts of the body (metastatic).
- You are able to care for yourself and be up and about (ECOG 0-1).
- You have not been treated with immunotherapy drugs for cancer before.
- You do not have an active autoimmune disease or untreated hepatitis B or C.
- You agree to use contraception during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—HRS-2189, adebrelimab, and BP102—for people whose colorectal cancer has spread. The goal is to see if this combination can help shrink tumors or slow the disease. It may be an option if standard treatments haven't worked.
This study tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.